Previous close | 199.50 |
Open | 201.50 |
Bid | 201.10 x 20000 |
Ask | 202.60 x 20000 |
Day's range | 201.50 - 203.40 |
52-week range | 126.40 - 218.20 |
Volume | |
Avg. volume | 24 |
Market cap | 29.881B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 32.91 |
EPS (TTM) | 6.18 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | 1.79 (0.90%) |
Ex-dividend date | 08 May 2024 |
1y target est | 261.67 |
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.